Stuttgart
30.03.26 | 21:55
51,50 Euro
0,00 % 0,00
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 51,50 | 53,00 | 30.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Dividendenbekanntmachungen (25.03.2026) | 6.533 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AFYA LIMITED KYG011251066 0,656 USD 0,5648 EUR ALTRIA GROUP INC US02209S1033 1,06 USD 0,9127 EUR ATLAS ARTERIA AU0000013559 0... ► Artikel lesen | |
| NOVONESIS A/S ADR Aktie jetzt für 0€ handeln | |||||
| 23.03. | Novonesis (Novozymes A/S): Resolutions from the Annual General Meeting 2026 | 1.466 | GlobeNewswire (Europe) | Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit... ► Artikel lesen | |
| 23.03. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 4 | GlobeNewswire (USA) | ||
| 23.03. | Novonesis & Hewlett Packard Enterprise Dividenden im global market - Ex-Tag 24.03.2026 | 35 | Wiener Börse | ||
| 16.03. | Novonesis (Novozymes A/S): Novonesis issues EUR 1.7 billion in bonds to refinance bridge facility | 478 | GlobeNewswire (Europe) | COPENHAGEN, Denmark - March 16, 2026. Novonesis has completed a EUR 1.7 billion bond issuance, with significant interest from a broad group of investors.
The transaction was primarily undertaken... ► Artikel lesen | |
| 13.03. | Novonesis (Novozymes A/S): Novonesis issues EUR 1.7 billion senior unsecured notes | 311 | GlobeNewswire (Europe) | On March 12, 2026, Novonesis, through Novozymes A/S, successfully priced and closed an aggregate principal amount of EUR 1.7 billion senior unsecured notes (the "Notes"). The issuance was completed... ► Artikel lesen | |
| 11.03. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 23 | GlobeNewswire (USA) | ||
| 09.03. | Novonesis named a Great Employer to Work For in North Carolina | 17 | GlobeNewswire (USA) | ||
| 26.02. | Novonesis (Novozymes A/S): Invitation to the 2026 Annual General Meeting | 7 | GlobeNewswire (USA) | ||
| 26.02. | Novonesis (Novozymes A/S): Trading by management and close relations of management | 5 | GlobeNewswire (USA) | ||
| 26.02. | Novozymes Reports Climb In Q4 Bottom Line | 517 | AFX News | BRUSSELS (dpa-AFX) - Novozymes (NVZMF.PK) reported earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings came in at EUR122.8 million, or EUR1.25... ► Artikel lesen | |
| 25.02. | Novozymes A/S Non-GAAP EPS of €1.49, revenue of €4.16B | 17 | Seeking Alpha | ||
| 25.02. | Novonesis Feb 2026 slides: biosolutions leader targets 39% margins by 2030 | 11 | Investing.com | ||
| 25.02. | Biosolutions-Marktführer Novonesis peilt bis 2030 eine Marge von 39 % an | 32 | Investing.com Deutsch | ||
| 25.02. | Novonesis A/S Bottom Line Climbs In Q4 | 16 | RTTNews | ||
| 25.02. | Novonesis (Novozymes A/S): Novonesis delivered strong organic sales growth of 7% in 2025 | 285 | GlobeNewswire (Europe) | COPENHAGEN, Denmark - February 26, 2026. Novonesis delivered strong organic sales growth of 7% and an adjusted EBITDA margin of 37.1% in 2025. The company expects a good start to 2026 and a good year... ► Artikel lesen | |
| 25.02. | Novonesis (Novozymes A/S): Novonesis' Annual Report 2025 | 21 | GlobeNewswire (USA) | ||
| 28.11.25 | Novonesis: JPM setzt Aktie auf Focus List - großes Potenzial | 70 | Investing.com Deutsch | ||
| 28.11.25 | JPMorgan hebt Kursziel für Novonesis auf 560 DKK an - starke Wachstumsaussichten | 43 | Investing.com Deutsch | ||
| 28.11.25 | JPMorgan raises Novonesis stock price target to DKK560 on strong growth outlook | 10 | Investing.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GENMAB | 226,80 | +0,22 % | Genmab A/S: Major Shareholder Announcement | ||
| INSMED | 134,00 | 0,00 % | Weekly Buzz: Corcept Therapeutics Wins FDA Nod In Cancer; Merck & Co. Acquires Terns Pharmaceuticals; Insmed Meets Trial Goals But Valneva Misses | KENILWORTH (NJ) (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Japan, EU withdrawals, mergers, and clinical trial data readouts spanning lung disease... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 276,44 | -4,53 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | ||
| QIAGEN | 34,540 | +1,75 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,510 | -0,68 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| RELAY THERAPEUTICS | 9,350 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| BULLFROG AI | 1,070 | 0,00 % | Bullfrog AI stock offers a rare opportunity for investors to take profit | ||
| ALUMIS | 20,130 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| BIONTECH | 74,25 | -0,07 % | JETZT über 50 % KURSPOTENZIAL!? BioNTech, TUI und Bayer-Partner MustGrow | Lust auf ein Investment in einen Geheimtipp mit riesigem Marktpotenzial? Dann ist die Aktie von MustGrow interessant. Das Unternehmen wird mit unter 40 Mio. CAD bewertet. Die biologischen und regenerativen... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,165 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ERASCA | 14,940 | 0,00 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| NUVALENT | 96,81 | +0,16 % | Wells Fargo stuft Nuvalent wegen hohem Medikamentenpotenzial mit "Overweight" ein | ||
| ARCELLX | 114,76 | +0,17 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| CG ONCOLOGY | 63,90 | -1,19 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| ARRIVENT BIOPHARMA | 21,010 | -1,82 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen |
NOVONESIS A/S ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 51,50 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NOVONESIS A/S ADR finden Sie auf Wallstreet Online.